A Study of Human Multi-Sensory Integration

NCT ID: NCT03498391

Last Updated: 2023-02-08

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-30
• Study Completion Date: 2023-05-31

Brief Summary

The primary aim of this study is to determine whether spatiotemporal characteristics of multisensory evoked potentials can be used as a marker of consciousness (awareness) under anesthesia.

The secondary aim is to characterize changes in the characteristics of evoked potentials under anesthesia in both single sensory modality (visual, auditory) and across sensory modalities.

Detailed Description

This is a prospective, dual parallel arm human subject study aimed at determining the relationship between level of sedation (consciousness) and features of multi and uni-sensory evoked potentials with the ultimate goal of developing novel means of detecting consciousness under anesthesia with potential for application to other clinical settings such as brain injury. For this purpose, the investigators have chosen two anesthetics with fundamentally distinct mechanisms of action: propofol and ketamine.

The study will involve healthy compensated volunteers. On the day of the study, an EEG cap will be applied to the participant for monitoring brain activity and an intravenous line will be placed for drug administration. Blood pressure, ECG, pulse oxymetry, and end-tidal carbon dioxide (from nasal cannula) will be monitored. Supplemental oxygen will be administered using a nasal cannula. Subjects will then perform the behavioral tasks in the awake state for approximately 1 hour.

After this phase is complete, participants will receive either propofol or ketamine (chosen permuted block randomization) using a clinician bolus/infusion strategy titrated to Richmond Agitation-Sedation Scale score of -1 (see above). Once the desired sedation level is achieved, subjects will once again complete the behavioral tasks. After the completion of this phase (approximately 1 hour) the anesthetic dose will be increased to attain Richmond Agitation-Sedation Scale -3 to -4. At this level of sedation subjects will not be able to do the behavioral task and only the evoked potentials will be recorded. Upon completion of this phase (approximately 1 hour), sedation level will be decreased to return the subject to a Richmond Agitation-Sedation Scale of -1 and once again the tasks will be repeated.

Finally, the anesthetic infusion will be stopped. Once the Richmond Agitation-Sedation Scale score of 0 is attained, participants will once again perform the behavioral task (approximately 1 hour). This will conclude the experimental phase of the trial. Subjects will be monitored until clinically established discharge criteria are met. This includes adequate respiration, blood pressure, oxygen saturation and activity level. No formal follow-up is required; however, subjects will be called 24 hours after study completion.

Conditions

Anesthesia Awareness

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Propofol

Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.

Group Type: EXPERIMENTAL

Propofol

Intervention Type: DRUG

Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.

Ketamine

Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.

Group Type: EXPERIMENTAL

Ketamine Injectable Product

Intervention Type: DRUG

Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.

Interventions

Propofol

Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.

Intervention Type: DRUG

Ketamine Injectable Product

Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.

Intervention Type: DRUG

Other Intervention Names

Diprivan; Ketalar

Eligibility Criteria

Inclusion Criteria

• Healthy volunteers ages 18-65 years old
• American Society of Anesthesiologists (ASA) Physical Status I or II (i.e. healthy)
• Body Mass Index <30 kg/m2
• Easily visible uvula

Exclusion Criteria

• Contraindications to administration of either propofol or ketamine
• Allergy to either one of the medications or preservative in which it is diluted.
• History (or current) seizure disorder
• Contraindications to anesthesia
• Significant cardiovascular disease (e.g. h/o hypertension, arrhythmias, myocardial infarction, congestive heart failure, congenital heart defects, coronary artery disease)
• Increased risk factors for difficult intubation and/or ventilation
• Obesity (BMI>=30 kg/m2)
• Mallampati class > 2.
• History of or current obstructive sleep apnea.
• Increased risk of aspiration
• Any per oral intake within 8 hours of anesthetic exposure
• Conditions that delay gastric emptying (e.g. obesity, hiatal hernia, gastro esophageal reflux disease, pregnancy, etc.)
• Pulmonary disease (e.g. chronic obstructive pulmonary disorder, asthma requiring rescue inhaler within last month, emphysema, pulmonary hypertension, pulmonary fibrosis etc).

• Neurological disease. Patients with history of strokes, seizures, brain surgery, brain tumor, increased intracranial pressure.
• Psychiatric disease. History of or presents of psychosis, schizophrenia, schizo-affective disorder.
• Specific Medication Current Use. History of or current intake of antipsychotics or sedatives.
• Drug abuse. History of or current use of illegal drugs such as stimulants or depressants.
• Pregnancy or breastfeeding
• Inability to provide informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Max Kelz, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

University of Pennsylvania, Perelman School of Medicine

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

829800

Identifier Type: -

Identifier Source: org_study_id